Myriad Genetics (NASDAQ:MYGN) Upgraded at Piper Sandler
Piper Sandler upgraded shares of Myriad Genetics (NASDAQ:MYGN – Free Report) from a neutral rating to an overweight rating in a research note issued to investors on Wednesday, Marketbeat Ratings reports. They currently have $12.50 target price on the stock, up from their previous target price of $11.50. MYGN has been the topic of a […]
Piper Sandler upgraded shares of Myriad Genetics (NASDAQ:MYGN – Free Report) from a neutral rating to an overweight rating in a research note issued to investors on Wednesday, Marketbeat Ratings reports. They currently have $12.50 target price on the stock, up from their previous target price of $11.50. MYGN has been the topic of a […]
